About the Company
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $APLS News
Which Is a Better Investment, Apellis Pharmaceuticals Inc or Avidity Biosciences Inc Stock?
Learn more about whether Apellis Pharmaceuticals Inc or Avidity Biosciences Inc is a better investment based on AAII's A+ ...
Apellis Pharmaceuticals Inc's Chief Scientific Officer Pascal Deschatelets Sells 69,107 Shares
Chief Scientific Officer Pascal Deschatelets sold 69,107 shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) according to a ...
Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's What You Should Know
I nvestors might want to bet on Apellis Pharmaceuticals, Inc. (APLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in ...
Apellis Pharmaceuticals Inc APLS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Apellis Pharmaceuticals, Inc. (APLS) Q4 and Full Year 2023 Earnings Call Transcript
Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen ...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee received 2,795 restricted stock units (RSUs). Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of ...
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief ...
Apellis Pharmaceuticals Inc (APLS) CTO Nur Nicholson Sells 11,220 Shares
Chief Technical Officer Nur Nicholson sold 11,220 shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) according to a recent ...
Apellis Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...